Haemodynamic and renal effects of tadalafil in patients with cirrhosis (Journal article)

Kalambokis, G. N./ Kosta, P./ Pappas, K./ Tsianos, E. V.

A recent report introduced the phosphodiesterase-5 inhibition by vardenafil as a novel treatment of portal hypertension in patients with cirrhosis. In the herein presented "letter to the editor", the administration of tadalafil did not influence portal haemodynamics but impaired systemic haemodynamics in patients with cirrhosis. Our observations concur with the results of a report in a previous issue of World Journal of Gastroenterology (October 2008). Moreover, tadalafil adversely affected renal function in patients with decompensated liver disease.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Carbolines/adverse effects/*therapeutic use,Hemodynamics/*drug effects,Humans,Hypertension, Portal/*drug therapy/etiology/physiopathology,Kidney/*drug effects/physiopathology,Liver Cirrhosis/complications/*drug therapy/physiopathology,Natriuresis/drug effects,Phosphodiesterase Inhibitors/adverse effects/*therapeutic use,Vasodilator Agents/adverse effects/*therapeutic use
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/21312
ISSN: 1007-9327
Link: http://www.ncbi.nlm.nih.gov/pubmed/20954291
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Kalambokis-2010-haemodynamic and renal.pdf531.63 kBAdobe PDFView/Open    Request a copy

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.